PND98 Real World IMPACT of Fremanezumab Treatment on Headache Frequency and Healthcare Resource Use Among US Patients with Episodic or Chronic Migraine
McAllister P, Casciano J, Cohen J, Thompson S, Krasenbaum L, Dotiwala Z, Tangirala K, and Lamerato L. PND98 Real World IMPACT of Fremanezumab Treatment on Headache Frequency and Healthcare Resource Use Among US Patients with Episodic or Chronic Migraine. Value in Health 2020; 23:S640.
Value in Health
Objectives: Fremanezumab, a fully-humanized monoclonal antibody (IgG2Δa) that selectively targets the calcitonin gene-related peptide (CGRP) pathway, has demonstrated efficacy in adults with episodic or chronic migraine in clinical trials and has been approved for migraine prevention in adults. However, real-world data on the effectiveness of fremanezumab are limited. This retrospective, observational cohort study assessed patient-reported headache frequency and healthcare resource utilization (HCRU) before and after fremanezumab treatment initiation. Methods: Data were extracted from September 2018 through June 2020 from the EMRClaims+®, an integrated health services database containing over 20 million medical records from national commercial insurance claims, Medicare claims, and regional electronic medical records. Patients included in the cohort analysis were aged ≥18 years and were administered fremanezumab, with enrollment or treatment history for ≥6 months prior to initiating fremanezumab (index date), and enrollment or treatment encounter for ≥1 month after the index date. Headache frequency was assessed at baseline and ≥1 month after fremanezumab initiation. Wilcoxon-signed rank tests were used to compare means of headache frequencies before and after fremanezumab initiation. Results: A total of 54 patients were eligible for analysis of headache frequency. Overall headache frequency decreased by 63% after fremanezumab initiation: mean (standard deviation [SD]) headache frequency was 22.24 (9.29) days per month pre-index versus 8.24 (7.42) days per month post-index (P <0.0001). Mean ER visits per month decreased from 0.72 to 0.54 (P = 0.003), and mean outpatient visits per month decreased from 1.04 to 0.81 (P = 0.0004). While mean hospitalizations per month also decreased, the result did not reach statistical significance (P = 0.095). Conclusions: Significant reductions in headache frequency and HCRU were observed after fremanezumab initiation overall and across episodic and chronic migraine groups in a real-world setting.